Northland Capital Cuts Rating of ImmuPharma PLC (LON:IMM) To a “Corporate”

June 14, 2018 - By Cecil Scoggins

ImmuPharma plc (LON:IMM) Logo

ImmuPharma PLC (LON:IMM) Receives a Downgrade

Northland Capital lowered ImmuPharma PLC (LON:IMM) shares to a “Corporate” rating in a research note sent to clients and investors today.

ImmuPharma plc (LON:IMM) Ratings Coverage

Among 3 analysts covering ImmuPharma PLC (LON:IMM), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. ImmuPharma PLC has GBX 1200 highest and GBX 181 lowest target. GBX 539.33’s average target is 2119.18% above currents GBX 24.3031 stock price. ImmuPharma PLC had 7 analyst reports since December 21, 2017 according to SRatingsIntel. Berenberg maintained ImmuPharma plc (LON:IMM) on Monday, April 16 with “Buy” rating. On Friday, March 23 the stock rating was maintained by Northland Capital with “Buy”. The firm earned “Buy” rating on Thursday, December 21 by FinnCap. Northland Capital maintained ImmuPharma plc (LON:IMM) on Thursday, December 21 with “Buy” rating. The firm has “Corporate” rating by Northland Capital given on Thursday, June 14. The company was maintained on Wednesday, January 24 by Northland Capital.

The stock increased 5.21% or GBX 1.2031 during the last trading session, reaching GBX 24.3031. About 1.66 million shares traded. ImmuPharma plc (LON:IMM) has 0.00% since June 14, 2017 and is . It has underperformed by 12.57% the S&P500.

ImmuPharma plc, a pharmaceutical company, develops drug candidates based on peptide therapeutics to treat serious medical conditions. The company has market cap of 33.90 million GBP. The companyÂ’s lead product candidate is the Lupuzor, which is in Phase III clinical trials for the treatment of lupus, an autoimmune chronic inflammatory disease. It currently has negative earnings. The Company’s other product candidates include IPP-204106, an anti-cancer nucleolin antagonis peptide program that has completed Phase I/IIa clinical trials to treat cancer; IPP-102199, which is in pre-clinical development stage to treat severe pain; IPP-201007 that is in early development stage for the treatment of inflammatory and allergic conditions, such as asthma and other respiratory disorders, rheumatoid arthritis, septic shock, and acute pancreatitis; and IPP-203101, a peptide antibiotic, which is in pre-clinical development stage for the treatment of lethal infections, including methicillin-resistant staphylococcus aureus and other hospital acquired infections.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.